SCHEMBL12345705

SCHEMBL12345705

CCCCCCCCCCCCCCCCOCC(COP(=O)(O)OCCC)OCCC(=O)O

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ LPAR1 Q92633 7/20 0.61
▸ LPAR3 Q9UBY5 7/20 0.61
▸ PLA2G2C Q5R387 3/20 0.56
▸ LPAR2 Q9HBW0 4/20 0.54
▸ P2RY10 O00398 6/20 0.49
▸ LPAR5 Q9H1C0 4/20 0.49
▸ RECQL P46063 1/20 0.46
▸ LPAR6 P43657 3/20 0.46
▸ LPAR4 Q99677 3/20 0.46
▸ FABP3 P05413 1/20 0.45
▸ GPR34 Q9UPC5 2/20 0.45
▸ PLCG2 P16885 1/20 0.44
▸ PIK3R1 P27986 1/20 0.44
▸ AKT1 P31749 1/20 0.44
▸ AKT2 P31751 1/20 0.44
▸ PIK3CA P42336 1/20 0.44
▸ AKT3 Q9Y243 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12345674 0.94 LPAR1 (0.64) LPAR1LPAR3PLA2G2CLPAR2P2RY10
SCHEMBL12345684 0.94 LPAR1 (0.64) LPAR1LPAR3PLA2G2CLPAR2P2RY10
SCHEMBL15166530 0.94 LPAR1 (0.64) LPAR1LPAR3PLA2G2CLPAR2P2RY10
SCHEMBL12345666 0.94 LPAR1 (0.64) LPAR1LPAR3PLA2G2CLPAR2P2RY10
SCHEMBL12345686 0.94 LPAR1 (0.64) LPAR1LPAR3PLA2G2CLPAR2P2RY10
SCHEMBL12345698 0.93 LPAR1 (0.61) LPAR1LPAR3PLA2G2CLPAR2P2RY10
SCHEMBL27966573 0.90 RECQL (0.59) LPAR1LPAR3PLA2G2CLPAR2RECQL
SCHEMBL12345737 0.88 P2RY10 (0.59) LPAR1LPAR3PLA2G2CLPAR2P2RY10
SCHEMBL12345664 0.86 PLA2G2C (0.67) LPAR1LPAR3PLA2G2CLPAR2P2RY10
SCHEMBL12345678 0.86 PLA2G2C (0.67) LPAR1LPAR3PLA2G2CLPAR2P2RY10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9206206-B2 Oxidized lipid compounds and uses thereof VASCULAR BIOGENICS LTD. (IL) 2015-12-08 — — US disclosed
US-20130203707-A1 Oxidized Lipid Compounds and Uses Thereof VASCULAR BIOGENICS LTD. (IL) 2013-08-08 — — US disclosed
US-20110207703-A1 OXIDIZED LIPID COMPOUNDS AND USES THEREOF VASCULAR BIOGENICS LTD. (IL) 2011-08-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130203707-A1 Oxidized Lipid Compounds and Uses Thereof LPO, GPX4, ALOX15B LPAR1 305/4885LPAR3 417/4885PLA2G2C 1093/4885
US-20110207703-A1 OXIDIZED LIPID COMPOUNDS AND USES THEREOF LPO, GPX4, ALOX15B LPAR1 305/4885LPAR3 417/4885PLA2G2C 1093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback